Onera Health announced its Series C funding round, amounting to €30 million, with Invest-NL contributing €5 million. The investment underlines Invest-NL’s commitment to making healthcare more accessible and improving the quality of life for patients with sleep disorders. It also aims to reduce healthcare costs for hospitals and clinics by introducing Onera Health’s innovative solutions in the field of sleep medicine. The funding will accelerate Onera Health’s production and implementation plans and expedite approvals for its second-generation polysomnography (PSG) system in Europe and the US. New investors EQT Life Sciences and Gimv led the round, with additional support from existing stakeholders including Innovation Industries, imec.xpand, BOM, and 15th Rock. Invest-NL focuses on keeping healthcare reachable, affordable, and staffable, emphasizing the transition of care from hospitals to patients’ home environments. Investment Manager Bram Sprangers expresses confidence in Onera Health’s groundbreaking diagnostic technology and its potential as a game-changer in sleep disorder diagnostics.
“Healthcare”, “Private Equity”, “Medical Technology”,”Netherlands”, “Europe”, “United States”
https://www.invest-nl.nl/page/2982/investering-leidt-tot-toegankelijk-slaaponderzoek-en-lagere-zorgkosten?lang=nl